Short radiotherapy with oral relugolix tested in intermediate-risk prostate cancer
Tests short-course radiotherapy plus oral relugolix in men with intermediate-risk localized prostate cancer.
Key facts
- Who runs it
- Fondazione Radioterapia Oncologica Onlus
- Where
- Aviano, Bergamo, Florence, Messina, Modena, Negrar, Palermo, Parma, Reggio Emilia, Rome, Rozzano, and Turin, ItalySee the 14 sites
- Trial code
- Registry title
- Ultra-hypofractionated radiotHErapy and concomitant oral RelugOlix for treatment of intermediate risk prostate cancer. (Ultra-HERO trial)
- Status
- Not yet recruiting
- Phase
- Phase 2
- People taking part
- 73 people, planned
- Started
- 3 Mar 2025
- Expected to end
- 30 Jun 2029
- Type of study
- Interventional
- Record updated
- 4 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for men with prostate cancer that has not spread and is at unfavourable intermediate risk. They would have short radiotherapy plus relugolix tablets.
- Age
- Over 18 years old.
- Sex
- Men only.
- Disease stage
- Prostate adenocarcinoma confirmed by biopsy, localized, unfavourable intermediate risk (Gleason 4+3 and/or more than 50% of biopsy cores positive and/or more than 2 intermediate risk factors).
- Earlier treatment
- People must be candidates for androgen deprivation therapy. They must be able to have ultra-hypofractionated radiotherapy of the prostate (IPSS < 15, prostate volume < 90 cc).
Main reasons for not taking part
- Neuroendocrine differentiation
- Metastatic disease at diagnosis
- Any high-risk feature (Gleason >4+3, >cT3a, PSA > 20 ng/ml)
- Heart attack, unstable heart disease or stroke in the past 6 months
- Uncontrolled hypertension
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- > 18 years old
- Signed informed consent
- Hystological confirmation of prostate adenocarcinoma
- Deemed suitable for ultrahypofractionated treatment on prostate (IPSS < 15, prostate volume <90 cc)
- Patients should be candidate to androgen deprivation therapy for the management of prostate cancer
- Unfavourable intermediate risk (GLeason 4+3 and or >50% of biopsy cores positive and or > 2 intermediate risk factor)
Who cannot take part
- Any contrahindication for ultrahypofractionated radiotherapy on prostate
- Participants with myocardial infarction, unstable symptomatic ischemic heart disease, cerebrovascular events, or any significant cardiac condition within the prior 6 months
- Metastatic disease at diagnosis (Patients will be staged with conventional imaging consisting of CT and/or bone scan and prostate MRI. PSMA imaging is allowed but not mandatory.)
- Uncontrolled hypertension
- Neuroendocrine differentiation
- Any high-risk feature (Gleason >4+3, >cT3a, PSA > 20 ng/ml)
- Active conduction system abnormalities
Where in Italy
- Centro di Riferimento Oncologico di AvianoAviano, ItalyNot yet recruiting
- Cliniche Gavazzeni S.p.A.Bergamo, ItalyNot yet recruiting
- Azienda Ospedaliero-Universitaria CareggiFlorence, ItalyNot yet recruiting
- Azienda Ospedaliera Universitaria Gaetano Martino MessinaMessina, ItalyNot yet recruiting
- Azienda Ospedaliero - Universitaria di ModenaModena, ItalyNot yet recruiting
- IRCCS Ospedale Sacro Cuore Don CalabriaNegrar, ItalyNot yet recruiting
- ARNAS Civico Di Cristina BenfratelliPalermo, ItalyNot yet recruiting
- Casa Di Cura Macchiarella S.p.A.Palermo, ItalyNot yet recruiting
- Azienda Ospedaliero Universitaria ParmaParma, ItalyNot yet recruiting
- Azienda USL IRCCS di Reggio EmiliaReggio Emilia, ItalyNot yet recruiting
- Fondazione Policlinico Universitario Agostino Gemelli IRCCSRome, ItalyNot yet recruiting
- Ospedale Isola Tiberina - Gemelli IsolaRome, ItalyNot yet recruiting
- Humanitas Mirasole S.p.A.Rozzano, ItalyNot yet recruiting
- Azienda Ospedaliera Universitaria Citta Della Salute E Della Scienza Di TorinoTurin, ItalyNot yet recruiting
About the trial
What the trial wants to find out
To assess rate of complete biochemical response after 6 months of treatment, defined as PSA <0.5 ng/ml, in an homogeneous cohort of patients affected by unfavourable intermediate risk localized prostate cancer undergoing prostate radiotherapy (36.25 GY in 5 fractions) + short course oral relugolix.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Ultra-hypofractionated radiotHErapy and concomitant oral RelugOlix for treatment of intermediate risk prostate cancer. (Ultra-HERO)
- Plain-language title
- Short radiotherapy with oral relugolix tested in intermediate-risk prostate cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 4 June 2026